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Summary
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and
investigational drug therapies that is contributing significantly to advancing
treatment in multiple disease areas, including inflammatory and autoimmune
diseases, genetic deficiencies and cancer. Unfortunately, unwanted
immunogenic responses to BPs, in particular those affecting clinical safety or
efficacy, remain among the most common negative effects associated with this
important class of drugs. To manage and reduce risk of unwanted
immunogenicity, diverse communities of clinicians, pharmaceutical industry
and academic scientists are involved in: interpretation and management of
clinical and biological outcomes of BP immunogenicity, improvement of
methods for describing, predicting and mitigating immunogenicity risk and
elucidation of underlying causes. Collaboration and alignment of efforts across
these communities is made difficult due to lack of agreement on concepts,
practices and standardized terms and definitions related to immunogenicity.
The Innovative Medicines Initiative (IMI; www.imi-europe.org), ABIRISK
consortium [Anti-Biopharmaceutical (BP) Immunization Prediction and
Clinical Relevance to Reduce the Risk; www.abirisk.eu] was formed by leading
clinicians, academic scientists and EFPIA (European Federation of
Pharmaceutical Industries and Associations) members to elucidate underlying
causes, improve methods for immunogenicity prediction and mitigation and
establish common definitions around terms and concepts related to
immunogenicity. These efforts are expected to facilitate broader collaborations
and lead to new guidelines for managing immunogenicity. To support
alignment, an overview of concepts behind the set of key terms and definitions
adopted to date by ABIRISK is provided herein along with a link to access and
download the ABIRISK terms and definitions and provide comments (http://
www.abirisk.eu/index_t_and_d.asp).
Keywords: ABIRISK consortium, anti-drug antibodies, biopharmaceuticals,
immunogenicity
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Introduction
Biopharmaceuticals (BP) comprise a diverse and rapidly
growing class of therapeutics that includes replacement fac-
tors for abnormal or deficient proteins, cytokines and
growth factors that modulate biological functions, mono-
clonal antibodies targeting components of disease path-
ways, fusion proteins and protein–drug conjugates, both
novel BP entities as well as copies of already licensed BPs,
designated biosimilars [1,2]. An unwanted consequence of
BP therapy is the development of immunogenic responses,
which in some cases have little or no impact but in other
cases affect safety significantly, with induction of infusion
reactions, hypersensitivity reactions and autoimmune syn-
dromes occurring due to cross-reactivity of anti-drug anti-
body (ADA) with endogenous counterparts of the BP
[3–6], and/or decreased efficacy related to neutralization of
the BP’s biological activity or increasing its clearance [7–9].
For these reasons, immunogenic potential of a BP is
determined during clinical trials by measurement and char-
acterization of ADA that develop during treatment; in
some cases, monitoring for biopharmaceutical and ADA
levels may be conducted during routine use of approved
BPs to guide patient care [10–12].
As the numbers of novel and biosimilar BPs continue to
increase, there is considerable interest in standardizing
methods for analysis and monitoring of immunogenicity
and improving its management based on knowledge of fac-
tors that contribute to its development and consequences,
including those related to the BP product itself, its mode of
administration and the underlying disease or patient char-
acteristics. These contributing factors are reviewed exten-
sively elsewhere [13–18]. Key concepts and recommended
definitions for standardizing the description and interpre-
tation of immunogenicity are described further below in
relation to practices for monitoring and mitigating immu-
nogenicity during clinical use of BPs.
ABIRISK recommendations
Many terms and concepts pertaining to immunogenicity, in
particular those pertaining to the reporting of ADA results,
have been in common use throughout the medical, scientific
and pharmaceutical communities involved in the use of BPs.
However, various disease areas and communities may have
used different terms or defined the same terms in inconsistent
ways. Furthermore, these communities have focused largely
on ADA, whereas data on cellular and pharmacogenomic
markers of immunogenicity, results from predictive immuno-
genicity methods and additional measurements and out-
comes of the anti-drug immune response (ADIR) that have
not been commonly applied previously to the study of BP
immunogenicity are now being generated. To bring this infor-
mation together and advance the scientific understanding and
clinical application of immunogenicity data, the ABIRISK
[Anti-Biopharmaceutical (BP) Immunization Prediction and
Clinical Relevance to Reduce the Risk; www.abirisk.eu] con-
sortium has developed and agreed to use a set of common
terms and definitions for describing immunogenicity of BPs.
As ABIRISK work proceeds, terms and definitions may
be added or refined as necessary to enhance the interpreta-
tion of ADIR data. To reach broader consensus, ABIRISK
will consult with other thought leaders, including the
ABIRISK scientific advisory board and key associations,
e.g. European Immunogenicity Platform (EIP), American
Association of Pharmaceutical Scientists (AAPS), American
and European Immunology Societies and regulatory
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agencies, some of which have already produced recom-
mended practices for development and validation of ADA
assays and assessment of immunogenicity risk profiles of
BPs now used routinely during development of new BPs
[19–24]. An AAPS focus group (AAPS Therapeutic Protein
Immunogenicity Focus Group) also recognized the need
for a harmonized approach for assessment and reporting of
clinical immunogenicity and has recently published recom-
mendations focused on terms and strategies related to
reporting ADA results for analysed samples and patient
populations [25], many of which have been adopted into
the ABIRISK terms and definitions; where applicable,
reporting of ABIRISK data will be consistent with those
recommendations. As data generated by ABIRISK will be
captured in a database, international efforts to create a
suite of orthogonal interoperable reference ontologies in
the biomedical domain will also be considered.
The comprehensive ABIRISK Terms and Definitions for
Reporting Immunogenicity Results (http://www.abirisk.eu/
index_t_and_d.asp) can be accessed at the ABIRISKwebsite
and comments may be provided at this site. Key concepts
and definitions are described further below in relation to
practices for monitoring and mitigating immunogenicity
during clinical use of BPs.
Patient populations (evaluated subjects)
and treatment history
The likelihood of development of immune responses and
consequences of such responses can vary among different
subject populations. Therefore, the meaningful interpretation
and application of the data generated from clinical research
of BPs will be highly dependent upon the knowledge of the
disease and treatment history of the subjects that were eval-
uated. Evaluations may involve analysis of healthy subjects
who have not been diagnosed with any disease, or patients
who have been diagnosed with any of the specific disease(s)
indicated for treatment with the BP. Differences in the
immune status, underlying disease and prior or concomitant
treatments (e.g. immunosuppressive drugs) have resulted in
ADIR differences among these populations. For example,
ADA differences reported in rituximab-treated low-grade or
non-Hodgkins lymphoma patients (11%), rituximab plus
methotrexate-treated rheumatoid arthritis (RA) patients
(11%) and adult patients with granulomatosis with polyan-
giitis (Wegener’s granulomatosis) and microscopic polyangii-
tis (MPA) treated in combination with glucocorticoids (23%)
(rituximab prescribing information [26]) are attributed to
the general immunosuppressive effects of prior treatments in
the cancer population and methotrexate-reducing immune
responses to the BP.
History of prior exposure as well as frequency, duration,
consistency of treatment and total BP doses administered
should be considered during immunogenicity risk assess-
ment. Treatment regimens may be highly variable, for
example with Factor VIII replacement therapy, where
patients may be treated only to control bleeding episodes,
sometimes receiving multiple treatments in a single day,
whereas other patients may be treated on a regular prophy-
laxis schedule to prevent bleeds [27]. For other BPs, treat-
ment regimens are more consistent. ‘Drug holidays’,
interruptions in a chronic dosing schedule, e.g. to reduce
adverse effects [28], have the potential to impact immuno-
genicity risk. Terms and definitions describing treatment
history are shown in Table 1.
The example in Table 2 shows how treatment days,
cumulative treatment days and total doses are determined
for individual subjects treated with a BP.
Because many BPs, in particular the monoclonal anti-
bodies, have long half-lives, the number of days of exposure
could be much greater than the number of treatment days.
The extent to which immunogenicity is affected by total or
cumulative doses, treatment or exposure days needs to be
determined for each BP. While determination of doses and
treatment days is relatively straightforward, exposure days
are related to BP concentrations, usually measured in
blood, and therefore dependent upon the analytical
method sensitivity and timing of measurements. Exposure
days may be determined based on BP measurements (e.g.
number of days over which BP concentration in plasma or
serum was above the assay limit of quantitation) or pre-
dicted by pharmacokinetic modelling (e.g. time divided by
BP mean half-lives).
Assessments of clinical outcomes may be conducted at
interim points throughout the duration of treatment or
beyond its discontinuation, thus time to end-point is an
additional variable to be taken into account in describing
the impact of immunogenicity on outcomes.
Development of anti-drug immune response (ADIR)
and characteristics of ADA
The ADIR is defined as the host immune system response
to an administered BP. Typically, assessment of BP ADIRs
has focused on adaptive ADA responses. However, it is
important to understand that ADIR encompasses innate
and adaptive immune systems. Either BP, co-administered
impurities or disease-specific factors may elicit pro- or
anti-inflammatory cytokines, chemokines and other signals
that may impact upon the efficiency of antigen presenta-
tion and BP-specific T and B lymphocyte adaptive
responses, ultimately determining whether the level of acti-
vation and maturation of B cells is sufficient to generate
high-titre, high-affinity or isotype-switched ADA responses
that could impact upon BP efficacy or mediate adverse
events such as hypersensitivity. Components of the innate
immune system and activated T lymphocytes also have the
potential to mediate adverse events such as infusion reac-
tions and delayed-type hypersensitivity. Thus, totality of the
Immunogenicity of biopharmaceuticals: ABIRISK recommendations
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BP ADIR should be considered when defining its immuno-
genicity profile. ADA is measured routinely in most BP clini-
cal studies and monitored for some BPs during clinical use,
while measurements such as the innate and T cell responses
described above have not been evaluated routinely.
Clinical consequences of BP immunogenicity are
dependent upon characteristics of induced ADA which, by
nature, is expected to be heterogeneous in composition,
containing a mixture of different quantities of antibodies of
different isotypes, specificities and affinities [31–33]. Low-
affinity, transient IgM responses may be induced initially,
but could be difficult to detect during routine ADA moni-
toring. However, immunoglobulin (Ig)M–BP complexes
may activate complement, which may play a role in media-
ting infusion reactions [34]. If the BP activates T helper
cells, switching to other classes or subclasses of ADA may
occur along with random somatic mutation of the immu-
noglobulin complementarity determining region (CDR)
genes, leading to production of ADA with higher affinity
for the BP, a phenomenon known as ‘affinity maturation’.
ADA isotype composition determines the potential for clin-
ical effects such as complement activation, antibody-
dependent cellular cytotoxicity (ADCC) and mast cell sensi-
tization, and interactions with the specialized neonatal Fc
receptor, which controls cross-epithelial and placental
transport as well as the serum half-life of ADA [35]. IgG4
has been associated with chronic BP administration and
high and persistent ADA responses to various BPs [36–40].
ADAs that bind epitope(s) close to the BP site of activity
(e.g. target binding site) are likely to block or ‘neutralize’
the BP biological activity [31,39,41,42]. ADAs bound to the
BP can affect the BP’s pharmacokinetics (PK) by either
increasing or decreasing clearance (referred to as clearing
and sustaining ADA, respectively) [9,43] and can also inter-
fere with quantification of BP in assays used to study PK
[44]. If the immune response to the BP continues, further
expansion and diversification of the BP-specific B cell
population may occur, resulting in ADA becoming more
diverse in its specificity for binding different structures on
the BP, a phenomenon known as ‘epitope spreading’. There-
fore, it is possible to observe low-affinity, non-neutralizing
ADA at early stages of an ADA response and higher affinity,
neutralizing ADA at later stages. Alternatively, ADA
responses may decrease and even disappear over time, even
when the BP treatment is being continued, due to the devel-
opment of immune tolerance [45,46]. Consequently, at any
given time point in an immune response, a unique mixture
of ADA characteristics may be present, resulting in the var-
ied ADA-associated clinical effects that can be observed
during the course of BP treatment.
Terms for ADA characterization are defined in Table 3.
ADA immune response assays
Considering the nature of ADA heterogeneity, it becomes
obvious that the use of reliable analytical methods and
thorough understanding of their limitations will be critical
to describe the ADA response appropriately and determine
potential relevance to clinical outcomes. A number of ADA
assay formats are available, each with some bias in the
type(s) of ADA measured and limitations in sensitivity and
susceptibility to interferences. Recommended practices for
Table 1. Terms and definitions describing patient biopharmaceuticals (BP) treatment history
Term Definition
Treatment-naive subject: Subject not exposed previously to the active substance in the BP
Treatment days* Days on which the subject received treatment with the BP
Exposure days* Days over which the subject was exposed to the BP
Total doses Total number of doses (administrations) of the BP received by the subject
Drug holiday Interruption in regularly scheduled dose administrations of a BP that is intended for
chronic administration on a regular schedule (e.g. weekly or monthly)
Cumulative treatment days Total number of days on which the subject received treatment with the BP
Cumulative exposure days Total number of days over which the subject was exposed to the BP
Time to end-point The length of time from initial treatment to measured end-point
*In the terminology used in clinical hemophilia literature [27] and the relevant European guidelines for clinical evaluation of therapeutic
hemophila products [29,30], the accepted definition of ‘exposure days’ is equivalent to the definition of ‘treatment days’ given in Table 1.
Table 2. Determination of cumulative treatment days
Treatment days and doses given
Subject no. Day 1 Day 8 Day 15 Day 22 Day 29 Cumulative treatment days Total (number of) doses
1 xx* xx xx xx xx 5 10
2 x x x 3 3
*x5dose given.
B. Rup et al.
388 VC 2015 British Society for Immunology, Clinical and Experimental Immunology, 181: 385–400
developing and validating ADA assays for use in clinical
development programmes have been developed through
multiple collaborative efforts among the pharmaceutical
and regulatory agencies and scientific communities under
the sponsorship of organizations such as AAPS and EIP
[19–24] and adopted into pharmaceutical regulatory
agency guidelines [47–50].
While most BPs are immunogenic under certain condi-
tions in some individuals, during the course of treatment
only a fraction of patients’ samples will typically have meas-
urable ADA levels, and therefore it is common practice to
first screen samples for ADA and then characterize any pos-
itives using a tiered approach, as recommended by Koren
et al. [23] (Fig. 1). Assay terms are defined in Table 4.
Using current technology and reagents, it is possible to
develop highly sensitive ADA screening assays capable of
detecting the most prevalent classes of ADA (IgM, IgG and
IgA); however, due to the low circulating levels of IgE, BP-
specific IgE is unlikely to be detectable in these assays,
therefore a separate IgE ADA assay may be required when
IgE detection is needed.
Cut-points for distinguishing positive and negative
sample results should be established initially based on a
statistical analysis of samples from the BP treatment-naive
patient population (if available) or from healthy donors.
In BP clinical studies, it is common practice to establish a
cut-point that allows sufficient sensitivity in order to
ensure the detection of most true positive samples, while
limiting the frequency of false negative results, i.e. a cut-
point set at the 95th percentile of the distribution of the
values obtained with BP treatment-naive donors, corre-
sponding to a 5% false positive rate. Samples scoring
below the screening assay cut-point are defined as ADA-
negative, whereas samples scoring equal to or above the
cut-point are then tested in the second tier of the immu-
nogenicity testing strategy, the confirmatory assay, in
order to further distinguish true positive from false posi-
tive samples.
Table 3. Terms and definitions for anti-drug antibody (ADA)
Term Definition
ADA Host antibody specific for the biopharmaceutical (BP) molecule. Includes all antibodies
that bind drug regardless of their functional activity. May include pre-existing and natu-
ral host antibodies cross-reactive with the BP (baseline ADA) as well as drug-induced or
boosted ADA. Preferred term to ‘binding antibody’ (Bab), as all ADA bind the BP
Affinity Refers to strength of a specific intermolecular interaction. Often expressed as an equilib-
rium dissociation or association constant (Kd/Ka) or ratio of dissociation/association
rate constants (kd/ka); however, due to the multivalent binding and heterogeneity of
affinities expected within a polyclonal ADA sample, other measurements (avidity, anti-
gen binding capacity, neutralizing capacity) may be more appropriate for characterizing
ADA–BP interaction
<Isotype/subclass-specific> ADA ADA measured in assay designed to detect ADA of specific isotype(s),
e.g. immunoglobulin (Ig)G ADA, BPIgG1 IgM ADA, IgE ADA
Neutralizing ADA (neutralizing antibody, NAb) ADA that inhibits or reduces the functional activity of the BP, as determined by an in-vitro
test method, regardless of its in-vivo relevance (i.e. whether or not the NAb causes
reduced efficacy)
Non-neutralizing ADA
(non-neutralizing antibody, non-NAb)
ADA that binds to the BP but does not inhibit its functional activity in an in vitro test
method, regardless of its in-vivo relevance (i.e. whether or not the non-NAb causes clini-
cal impact)
Clearing ADA ADA associated with increased clearance of the BP relative to its clearance rate in the
absence of ADA
Sustaining ADA ADA associated with apparent decreased clearance of the BP relative to its clearance rate in
the absence of ADA; most frequently observed when the BP has a fast clearance rate rel-
ative to the rate of IgG clearance
Anti-<component/domain etc.> ADA ADA against a particular component/domain of a BP, e.g. anti-Fc, anti-Fab,
anti-receptor domain, anti-polyethylene glycol (PEG) moiety
Anti-idiotypic ADA ADA specific for epitope(s) unique to a specific monoclonal antibody therapeutic; usually
ADA specific for the unique antigen-binding/complementarity determining region
(CDR) of monoclonal antibody (mAb) biopharmaceutical
Anti-allotypic ADA Generally refers to ADA specific for allotypic (defined as a genetically inheritable determi-
nant common to some but not all human immunoglobulin molecules) epitopes of a
mAb or mAb fragment BP. Could also refer to ADA specific for allotypic determinants
on non-immunoglobulin-based BPs
Immunogenicity of biopharmaceuticals: ABIRISK recommendations
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The confirmatory assay usually consists of a competitive
inhibition assay, in which samples are tested spiked and
unspiked with an excess of the BP. The excess BP binds the
specific ADA, preventing it from binding to the assay cap-
ture reagent, thus causing an inhibition in signal in the
assay relative to the signal generated by the unspiked sam-
ple. Confirmatory assay cut-points are usually set in order
to report a low percentage (typically 1–01%) of false posi-
tive samples using BP treatment-naive patient samples (if
available) or samples from healthy donors and determining
the percentage of signal inhibition corresponding to the
99th or 99.9th percentile of the distribution. Samples
spiked with BP that exhibit reduced signal (% inhibition)
in the assay relative to their respective unspiked signal at or
above the confirmatory assay cut-point (% inhibition) are
considered positive for BP-specific ADA, while those that
score below the cut-point are considered negative for BP-
specific ADA (false positive).
Qualitative ADA results (positive/negative) may be sup-
plemented with quasi-quantitative measurements of the
relative magnitude of ADA responses (e.g. titres or units)
to provide more useful information for interpretation of
ADA data and determining relationships to clinical out-
comes. However, it is neither accurate nor meaningful to
report ADA data in absolute quantitative readouts (i.e.
units of mass concentration) calculated from a positive
control antibody curve. Quantitative measurements of
mass concentration require standards with the same com-
position as the unknown samples, while the spectra of
ADA affinities, isotypes and epitope specificities are
expected to differ in composition across patients and across
time-points during the treatment of an individual patient.
Therefore, it is not possible to establish standards or assay
calibrators that are representative of the complex heteroge-
neity of ADA in all samples. Hence, ADA data should typi-
cally be reported using quasi-quantitative units, such as
titres, which are usually determined by running positive sam-
ples in a dilution series and reporting the titre as the recipro-
cal of the last dilution at which the sample scores above the
cut-point or the dilution that scores at the cut-point, calcu-
lated based on interpolation. Data from relative concentra-
tion assays should be designated clearly as ‘units of relative
concentration’, or preferably reported in other quasi-
quantitative units defined relative to a known amount of an
ADA-positive control sample. Other more quantitative meas-
urements such as binding affinity and in-vitro antigen bind-
ing or neutralizing capacity have also been reported [51,52];
however, these are cumbersome to perform on large numbers
of samples and results may also be affected by ADA heteroge-
neity and the assay system used.
It is important to note that the statistically established
cut-points used to identify positive samples are bioanalytical
cut-points that reflect the analytical variability of the assay
and biological variability of the treatment-naive study popu-
lation. Therefore, they are not ‘clinically relevant’, in the sense
that identifying a sample as positive for ADA is not an indi-
cator that the level of ADA present in the sample is sufficient
to cause a biologically or clinically meaningful effect (e.g.
alter PK, efficacy or cause adverse effects). However, sensitive
assays capable of detecting all ADA present help establish
definitively whether there are any relationships between clini-
cal effects and the measured ADA when initially studying the
immunogenicity profile in clinical studies. Where sufficient
clinical data demonstrating a clear relationship between ADA
positivity or titres, and clinical effect are available, it may be
possible to establish a ‘biological’ or ‘clinical’ for subsequent
use to distinguish clinically relevant from irrelevant ADA
responses. Sensitive ADA assays are also needed to correlate
ADA development with underlying causes of immunogenic-
ity and identify markers of immune response; e.g. markers of
early events in triggering an immune response to the BP or
indications of incomplete activation of the immune system
that could lead to immune tolerance by the BP.
Other assays may be developed to characterize ADA-
positive samples further and provide additional data to
understand and interpret more extensively the clinical rele-
vance of the ADA response to a BP. For example, an assay
that specifically measures ADA that neutralize the
Fig. 1. Typical tiered testing scheme for anti-drug
antibody (ADA) testing and characterization. In
the first tier, all evaluable samples are run in the
screen assay. Samples that score positive in the
screen assay are then analysed in a confirmatory
assay (tier 2). Samples that score positive in the
screen and confirmatory assay are reported as
positive, while samples that score negative in
either the screen or confirmatory assay are
reported as negative. Further tiered testing of
positive samples frequently includes analysis of
titres and neutralizing activity. In some cases,
isotype analysis or epitope mapping may also be
performed.
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biological effect of the BP may be useful in determining the
impact of ADA on pharmacodynamic effect or efficacy
while an assay that measures BP-specific IgE or IgM may
help to identify the underlying cause of a hypersensitivity
reaction.
A variety of different formats may be used for screening,
confirmatory and characterization assays, and limitations
are associated with each. Some tend to be more sensitive
for the detection of high-affinity ADA while others tend to
be more sensitive for detection of low-affinity ADA
[53,54]; some are biased against detection of certain classes
of ADA and some more susceptible to interferences by BP,
BP target or other serum components that may be present
in samples [19,22,55–60]. Table 5 summarizes analytical
issues encountered with these assays. BP or drug interfer-
ence is considered one of the most common and significant
issues, as steady state trough levels of many BPs are fre-
quently above the levels that could potentially interfere
with reliable ADA detection. ADA–BP immune complexes
present in samples may interfere with detection of either
ADA or BP levels and therefore may contribute to under-
reporting of ADA prevalence and incidence in the study
population and erroneous BP PK characterization profiles
[61]. The concentration of BP that interferes with ADA
detection will be highly dependent upon the ADA levels in
the sample (i.e. the drug tolerance level will be higher for
samples with higher levels of ADA and lower for samples
with lower levels of ADA). Whenever possible, drug inter-
ference should be minimized using various strategies,
including sample acidification pretreatment, more drug-
tolerant assay formats and platforms, use of competing
antibodies or monovalent versions of multivalent BP and
Table 4. Terms and definitions for anti-drug antibody (ADA) assays
Term Definition
ADA assay Bioanalytical method used to determine if a sample is qualitatively positive or negative for ADA and that can
provide quasi-quantitative information about the amount of ADA (typically reported as an antibody titre).
Often considered synonymous with binding ADA assay (assay designed to detect antibodies that bind the
biopharmaceutical (BP) regardless of the functional activity of the ADA) and total ADA assay (assay that
measures all ADA in the sample, although usually not capable of binding immunoglobulin (Ig)E due to its
low levels).
Free ADA assay ADA assay that measures ADA not bound to the BP. Generally a binding ADA assay can be considered a free
ADA assay unless specific ADA–BP dissociating conditions are incorporated into the assay procedure.
<Isotype/subclass x> ADA assay ADA assay designed to detect ADA of specific isotype(s) or group of isotypes; e.g. IgE ADA assay
Neutralizing antibody assay Assay used to determine whether ADA in a sample can neutralize some aspect of drug activity. Encompasses
bioassay (cell-based or enzymatic) or competitive ligand-binding assay
<Epitope/domain> ADA assay Assay designed to detect ADA specific for a particular epitope or domain of the BP, e.g. Fab assay
Screening assay In a tiered testing strategy, the assay used to distinguish potentially positive samples (based on screening
cut-point) versus negative samples
Confirmatory assay An assay conducted on samples found to be potentially positive in the screening assay in a tiered testing
strategy to identify false and true positives (based on confirmatory cut-point)
ADA characterization assay Investigational assay that is designed to obtain additional information on the specificity or type of antibodies
present in a sample. Information obtained from these assays may include, but is not limited to, the follow-
ing: titre, neutralizing antibody assay, isotyping assay (see definitions below and above)
Qualitative assay Assay that reports test results as positive/negative
Quasi-quantitative Assay Assay that reports a relative magnitude of ADA present in a sample (e.g. ADA titre)
Titre assay A quasi-quantitative assay providing titre as the unit of the amount of antibody in a sample. The titre is
often defined as the reciprocal of the lowest dilution of a sample generating a signal that is above the assay
cut-point. Alternatively, the titre is defined as the reciprocal of the dilution of a sample generating a signal
that is equivalent to the assay cut-point, calculated by an interpolation formula provided in an assay-
specific bioanalytical method
Relative concentration assay A quasi-quantitative assay providing sample results reported in relative mass units, determined by comparing
the assay signal generated by the sample relative to a signal generated by a diluted positive control sample.
Because the positive control generally contains a different mixture of antibodies than the sample, concen-
trations reported by this result are generally not accurate and should be reported as ‘relative concentra-
tions’ or defined units
Cut-point An assay signal threshold that distinguishes positive samples from negative samples, as defined in an assay-
specific analytical procedure. The cut-point is usually set based on statistical analysis with treatment-naive
samples representative of the study population (bioanalytical cut-point) but could be based on a biological
(e.g. change in pharmacodynamics marker; biological cut-point) or clinical end-point (e.g. loss of efficacy;
clinical cut-point). Cut-points are typically set for each assay in the tiered analysis strategy (screening
assay, confirmatory assay, neutralizing assay cut-points)
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longer incubation times [39,59,62–65]. However, there are
caveats to each of these strategies, as they may dissociate
incompletely the immune complexes, may denature and
reduce the binding activity of some ADA, may reduce
detection of ADA against some epitopes or may increase
the level of target interference. While drug interference
could result in under-reporting of ADA data, target inter-
ference, due to the presence of multi-valent BP target mole-
cules in samples, have been reported to cause false positive
ADA assay results in the bridge assay format [55,56].
Because of the potential for BP, BP target or serum compo-
nent interferences, ABIRISK includes the definition of an
‘inconclusive’ sample: ‘for which the assay result cannot be
reported as incontrovertibly negative or positive for ADA’,
and recommended that any positive or negative results that
could be questionable due to assay limitations should be
noted in reporting the results and considered in interpreta-
tion of the clinical or analytical outcomes. Because of these
various known assay limitations, described above and in
Table 5, whenever possible ADA data should be interpreted
in combination with pharmacokinetic (or BP concentra-
tion), pharmacodynamic and efficacy and safety data to
define the immunogenicity profile of the BP and determine
the clinical relevance.
Prior to use, ADA assays should be validated analytically
to assure reliable performance over time and establish which
changes in ADA measurements are likely to be meaningful
[20,22,47,49,50]. Analytical validation typically involves anal-
ysis of positive and negative quality control (QC) samples to
characterize inter- and intra-assay variability (precision), sen-
sitivity to small changes in conditions (robustness) and inter-
laboratory variability (ruggedness). As noted previously, it is
not possible to identify a positive control that contains a rep-
resentative mixture of the ADAs present in all samples, there-
fore caution should be used when translating information on
performance of positive controls to performance of actual
study samples. In particular, parameters such as sensitivity
and drug tolerance are unique to the properties of the posi-
tive control and will differ for individual patient samples.
While assays should be validated analytically for use in BP
clinical research, a higher standard would be needed to dem-
onstrate that the assay is clinically validated, in particular
that it correlates with clinical outcomes [i.e. correlates with
loss of efficacy (LoE) or pharmacodynamic response], such
that it may be used for clinical treatment decision-making.
Study design, patient monitoring and analysis
of ADIR results
In order to establish a clear causal relationship between
presence or type of ADA and safety signals or LoE in
patients, time-points at which ADA are measured should
be scheduled as closely as possible to time-points for safety
or efficacy measurements. For example, the chance of iden-
tifying clearing ADA or neutralizing antibody (Nab) as the
cause of LoE would be enhanced if a sample(s) collected
from the patient near time of observed LoE is determined
to be positive for these parameters. To comprehend rele-
vance to patient safety and efficacious response and to
define the immunogenicity risk profile of the BP in the
Table 5. Analytical issues encountered in anti-drug antibody (ADA) measurement
Issue Definition and explanation Mitigation or investigational strategies
Drug interference Alteration in ADA detection (usually impaired
detection) in an assay due to the presence of
biopharmaceuticals (BP) in the sample
Adjust sample collection time-points to achieve no/lowest BP
concentrations (before administration, after washout,
during drug holiday); utilize assay formats with a higher
degree of drug tolerance (bridge assay, high-density surface,
long incubation times); incorporate dissociation step prior
to analysis
Target interference Alteration in ADA detection. In bridge assay for-
mats, multivalent target may cause false positive
results (note target levels can increase after BP
administration)
Evaluate potential target interference during validation;
remove or denature target; add anti-target monoclonal
antibodies (mAbs) to block bridging
Pre-existing antibodies Antibodies reactive with the BP before initiation
of treatment
Affinity removal of antibodies or select pool of negative
samples to establish negative control. Statistical analysis to
identify true negative population for establishing negative
control cut-point. Establish individual cut-points using
baseline samples. Evaluate increases and decreases from
baseline in final population analysis to determine level of
BP-induced ADA
Rheumatoid factor
(RF) interference
Rheumatoid factor present in sample may elicit
positive result
Evaluate potential RF interference during validation; use assay
formats that minimize RF interference. Evaluate increases
and decreases from baseline in final population analysis to
determine level of BP-induced ADA
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patient population, ADIR results should be evaluated at the
sample, patient and population levels.
As described previously, ADA sample results are
reported typically as positive or negative based on a tiered
analysis approach (Fig. 1). These results can then be used
to determine the ADA status of patients as well as whether
they have had treatment-induced or treatment-boosted
responses (Fig. 2, Table 7). Typically, subjects are expected
to be negative prior to BP exposure; if a subject becomes
positive after treatment, the subject is designated as having
a treatment-induced ADA response. It is well recognized
that some BP treatment-naive subjects may have pre-
existing antibodies to the BP [66,67], which may originate
from the natural population of antibodies or from expo-
sure to cross-reactive environmental antigens or other BPs
containing the same or homologous ingredients. Cases in
which exposure to the BP results in post-treatment
increases in ADA titres relative to a positive baseline titre
are referred to as treatment-boosted ADA responses; in
other cases, exposure results in no post-treatment increases
in ADA titres relative to the baseline titres (treatment unaf-
fected). Over time, ADA titres may persist at the same level,
increase (persistent response) or decrease or become nega-
tive (transient response). When sample collection is infre-
quent or sporadic, it may be difficult to establish
persistence or transience of the response. None the less, in
many cases, merely designating whether a subject has devel-
oped ADA or was positive at some point during the study
may be insufficient to demonstrate causal relationships
between ADA and clinical outcomes.
ADA frequency in a population should be described with
the terms of incidence and prevalence (Table 6). Incidence is a
cumulative measurement of the number of subjects who,
within a defined period of time, have developed an immune
response to the BP (includes treatment-induced and
treatment-boosted responses), and is useful to predict the
probability that a particular BP will induce an ADA response
in that population. Prevalence is a measure of the number of
subjects who are positive at a particular time or during a par-
ticular time-frame and is most useful to assess relationships
between ADA and clinical outcomes, particularly when the
outcomes are immediately apparent (e.g. type I or
immediate-type hypersensitivity response due to IgE ADA or
LoE due to NAb development in haemophilia). When clinical
outcomes are delayed (e.g. LoE in multiple sclerosis), preva-
lence within the study or interim measurements of incidence
may be more useful to assess the clinical relationship.
Table 7 shows the proposed interpretation of ADA
status, induced and boosted ADA and prevalence and inci-
dence based on different patterns of ADA results. Although
vast differences in study design and immunogenicity data-
reporting strategies can be observed across published stud-
ies, common concepts and terms can be applied retrospec-
tively in describing these study designs and results for
comparative purposes as indicated in Table 8.
Establishing clinical relevance of an ADA response
Once ADA status and response of individual subjects and
incidence and prevalence for the study population have been
determined, their association and potential relationship to
PK/PD profiles, efficacy and safety outcomes should be eval-
uated. Patients could be stratified into various groups (for
example: positive/negative for ADA, NAb or pre-existing
antibodies; for boosted or induced ADA; based on time of
ADA onset; transience, persistence and duration of response;
or relative magnitude of ADA or NAb) for comparison of
clinical outcomes and immune response measurements.
Rationale and reliability of stratification approaches should
be determined for each patient population being studied.
In some cases, causal relationships can be identified
from a limited amount of clinical experience. However, due
to the different types of ADA responses that may develop
over time, it is expected that some associations between
treatment and risk of ADA development and between ADA
development and clinical consequences of ADA may be
subtle, requiring extensive accumulation of clinical data
and multivariate analysis to identify or establish causal rela-
tionships. Relationships can be especially challenging to
discern when the underlying disease and/or drug pharma-
cology affect the immune system.
For most BP, it is common practice to conduct immuno-
genicity monitoring in pre- and post-marketing clinical tri-
als. For products with higher immunogenicity risk, longer-
term monitoring during chronic treatment may be neces-
sary. However, there are no common practices to generate
and analyse these data to understand fully the immunoge-
nicity profiles of BPs used in various treatment scenarios.
Several recommendations have been made for common
approaches to presenting and analysing ADA data, includ-
ing receiver operating characteristic (ROC) curves, to esti-
mate clinically relevant thresholds of variables such as titre,
Fig. 2. Interpretation of anti-drug immune response. After sample
results have been determined, it will then be possible to categorize
the anti-drug antibody (ADA) status of the subjects, and determine
whether the positive subjects’ ADA originated from treatment
induced, boosted or unaffected ADA responses.
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Table 6. Terms for anti-drug antibody (ADA) response origin and frequency
Term Definition
Treatment-induced ADA-positive subject Subject with ADA developed de novo (seroconverted) following biopharmaceuticals
(BP) administration (i.e. formation of ADA any time after the initial drug
administration in a subject without pre-existing antibodies)
Treatment-boosted ADA-positive subject Subject with pre-existing antibodies that develops an increased level of ADA follow-
ing BP administration (i.e. any time after the initial drug administration the
ADA titre is disproportionately greater by a biologically relevant margin, such as
two- or threefold relative to the baseline titre)
Treatment-unaffected ADA-positive subject Subject with pre-existing ADA level that does not change following the BP
administration
Incidence of ADA (rate of ADA development) Measure of the rate of BP-specific ADA immune responses during a defined obser-
vation period, usually equal to the sum total of treatment-induced and
treatment-boosted ADA-positive subjects (but not treatment-unaffected) as a per-
centage of the evaluable subject population. Incidence is a cumulative measure-
ment. Incidence rates for treatment-induced ADA treatment-boosted ADA, or
specific types of ADA [e.g. non-neutralizing antibodies (Nabs) or immunoglobu-
lin (Ig)E] may also be considered separately. Incidence includes transient and
persistent positive patients and may also be referred to as cumulative incidence
Prevalence of ADA (frequency of ADA-positive subjects) The percentage of subjects positive for ADA in a defined population at a particular
time-point or within a particular defined time-frame. For example, antibody
prevalence at baseline (pretreatment) is determined by dividing the number of
evaluable subjects with antibody-positive pre-treatment samples by the number
of subjects with a pretreatment sample result, expressed as a percentage. May
also be useful when subjects with diverse treatment histories are sampled
randomly
Table 7. Interpretation of anti-drug antibody (ADA) status, prevalence and incidence
Time-point (month)
Baseline M0 M1 M3 Last M9 Follow-up M18
Sample result neg/pos
Subject no. Sample result titre (ns5no sample) ADA status Induced ADA Boosted ADA
1 Neg Neg Neg Neg Neg Neg Neg
2 Neg Neg Pos Pos Neg Pos Pos
225 1350
3 Neg Pos Pos Neg Neg Pos Pos
75 225
4 Pos Pos Pos NS Pos Pos Neg
225 225 225 225
5 Pos Pos Pos Pos Pos Pos Pos
75 1350 16200 8100 16200
6 NS Pos Pos Pos Pos Pos
75 225 75 225
Prevalence 40% 67% 83% 60% 50% In study: 83% (5/6)
n5 2/5 n5 4/6 n5 5/6 n5 3/5 n5 3/6
Incidence 60% n = 3/5
In this example, subject 1 remained negative throughout the study while subjects 2–6 had one or more positive samples and are therefore desig-
nated ADA-positive. Because subjects 2 and 3 were negative at baseline and were positive at one or more post-treatment time-points, both are
considered positive for treatment-induced ADA. Subjects 4 and 5 were positive at baseline but only subject 5 had a post-treatment increase in
titre, therefore subject 4 is negative for boosted ADA response while subject 5 is positive for boosted ADA response. At the time of the follow-up,
subjects 2 and 3 had become negative and were therefore considered transient immune responders. The prevalence at each time-point was calcu-
lated based on the no. of positive subjects at each time-point as % of/no. of evaluable subjects at that time-point and the incidence was calcu-
lated as the no. of subjects positive for induced or boosted ADA as % of no. of evaluable subjects in the study. Because subject 4 had no sample
at M9 and subject 6 had no sample at M0 (baseline), they were not evaluable for calculation of prevalence at M9 or incidence across the study.
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Table 8. Descriptions of immunogenicity reported in studies of approved biopharmaceuticals using ABIRISK recommended terms and definitions
(definitions in [] are study-specific definitions defined in the publications)
BP and study
designation, study
population
Assays: types of assays
(and reported results)
used)
Samples:
times of
collection
Samples:
ADA/NAb status
definitions
ADA status of subject
population
NAb status of subject
population
Natalizumab
AFFIRM study
in: treatment naive
MS patients [68]
ADA:
ELISA bridge assay:
screening (qualita-
tive)
and titre (quasi-
quantitative)
NAb: cell-based block-
ing bioassay;screen-
ing and titre assays
Baseline, then
every 12 weeks
over 2 years
ADA:
cut-point: OD of 50
lg/ml calibrator con-
trol;
positive sample:
OD cut-point OD;
Titre: sample
dilution with
OD5 cut-point
NAb: reduced fluores-
cence intensity from
bound
phycoerythrin-
conjugated natalizu-
mab below predeter-
mined limit
ADA-positive subjects:
9% (57/625)
Persistent positive
[ADA positive at 2
or more time-points
6 weeks apart]
subjects:
6% (37/57);
Transient-positive
[ADA-positive at a
single time point]
subjects:
3% (20/57)
Incidence of ADA:
9%
NAb-positive subjects:
100% of ADA-
positive subjects
Interferon-b PRISMS
study
in: treatment-naive
MS patients treated
with 44 lg three
times weekly
(TIW) or 22 lg
TIW [69]
ADA:
ELISA direct bind-
ing assay. Screening
(qualitative), con-
firmatory, and titre
(quasi-quantitative)
NAb: cell-based bioas-
say: VSV-induced
cytopathic effect
(CPE) assay (quasi-
quantitative)
Baseline, then
every 6 months
over 4 yrs
ADA:
cut-point: 2 s.d.
above mean OD for
pooled normal
human serum.
Positive sample:
OD> cut-point OD
and positive in con-
firmatory assay
NAb: Cut-point:
titre 20 NU/ml
where NU5 (f x N)/
10 and f5 1/sample
dilution at ED50, and
N5 IFN concentra-
tion (LU/ml)
ADA-positive subjects:
44% (82/186) at 22
lg TIW;
37% (67/182) at 44
lg TIW;
41% overall
NAb-positive subjects:
30% (55/186) at 22
lg TIW;
19% (35/182) at 44
lg TIW;
24% overall;
Persistent positive
[NAb positive at
final assessment]
subjects: 24%
(44/186) at 22 lg
TIW;14% (26/182)
at 44 lg TIW;19%
overall
Factor VIII Turocto-
cog alfa study
in: treatment-
experienced sub-
jects with severe
hemophilia A with
no history of Nabs
[70]
NAb:
non-cell-based bio-
assay: Nijmegan-
modified Bethesda
inhibitor assay clot-
ting assay (quasi-
quantitative)
Visits 1, 2, 4,
5, 6, 7, 8, 9
NAb:
cut-point: Bethesda
units (BU)> 06
NAb-positive subjects:
[patient tested posi-
tive >06 BU in 2
consecutive test
samples];
0% (0/150) of
patients developed
NAbs
Infliximab
re-initiation study
in: treatment-
experienced
patients who
restarted infliximab
after drug holiday
[71]
ADA:
acidification pre-
treatment homoge-
nous mobility shift
assay (quasi-quanti-
tative) [72]
T–1, T0,
T 11,
T 12*
ADA:
cut-point: 7.95 U/ml
[1 unit correspond-
ing to signal gener-
ated by positive
control serum
approx. 0.18 mg]
ADA-positive subjects:
13.3% at T–1*;
0% at T0 (0/124);
40% at T11 (31/77);
29% at T12 (19/65)
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onset and duration of ADA, and the Classification and
Regression Tree (CART) ‘partition’ analysis to predict categor-
ical or continuous clinical outcomes [25]. Several recent pub-
lications have proposed mathematical modelling approaches
to assess the impacts of ADA on PK and of BP exposure on
ADA development [9,43,74–76]. Depending on the risk level
and clinical impact, ADA or NAb testing for approved BPs
may be performed either routinely to monitor treatment or
only if needed, based on clinical observations such as altered
PK, loss of efficacy or AEs. For example, testing for neutraliz-
ing antibodies is routine in haemophilia treatment [12,27],
while ADA testing may be performed only in tumour necrosis
factor (TNF)-a antagonist non-responders who have low or
undetectable drug concentrations after treatment [10,11].
ABIRISK is evaluating data analysis strategies actively. Appro-
priate strategies to utilize ADIR data in treatment decisions
may need to be developed for each BP.
Contributions of ABIRISK
Data from ABIRISK pertaining to immunogenicity devel-
opment, prediction and safety will be collected in a single
database, requiring standardization of information origi-
nating from multiple types of investigational designs (e.g.
prospective and retrospective investigations), multiple BPs
(including coagulation factor VIII, b-interferons, TNF-a
antagonists, natalizumab and rituximab), different diseases
(e.g. haemophilia A, multiple sclerosis, rheumatoid arthri-
tis, other autoimmune rheumatic conditions, inflammatory
bowel diseases), different cohorts for a given disease and
various preclinical, clinical and immune monitoring fac-
tors. ABIRISK will collect and publish data in accordance
with the recommended terms and definitions and promote
their use in the broader communities.
Conclusions
Production of ADA represents one outcome of a complex
ADIR process that follows initial exposure to a BP and
involves innate and adaptive immune responses. To mini-
mize the risk of ADA induction and sustain BP efficacy,
insight into the complex mechanisms that drive ADIR is
needed, including characteristics intrinsic to the molecular
Table 8. Continued
BP and study
designation, study
population
Assays: types of assays
(and reported results)
used)
Samples:
times of
collection
Samples:
ADA/NAb status
definitions
ADA status of subject
population
NAb status of subject
population
Adalimumab Long-
term follow-up
study
in: treatment-naive
RA patients [73]
ADA:
radioimmunoassay
(qualitative and
quasi-quantitative)
Baseline, 4, 16,
28, 40, 52,
78, 104, 130,
156 weeks
ADA:
cut-point:12 AU
(arbitrary units)/ml
[1 AU defined based
on signal generated
by  12 ng of a pos-
itive control serum]
ADA-positive subjects:
[titres> cut-point on
at least 1 occasion in
combination with
serum adalimumab
levels< 5.0 mg/l]:
28% (76/272)
Adalimumab assay
comparison study
[65](from study
above [73])
ADA assays:(a–d)
radioimmunoassay
with
(a) no modification
(b) acidification
(c) acidification1
anti-
adalimumab
Fab idiotype
(d) overnight incu-
bation at 37C
(e) bridge format
electrochemilu-
minescent with
acidification
(qualitative and
quasi-
quantitative)
Baseline, 16,
28, 52
weeks
ADA:cut-points for
assays (a–e):
(a) 12 AU (arbitrary
units)/mL
(b) 30 AU/ml
(c) 48 AU/ml
(d) 33 AU/ml
(e) 39 AU/ml
ADA positive subjects
[titres> assay cut-
point on at least 1
time point] in
assays (a–e):
a) 149%
b) 660%
c) 511%
d) 574%
e) 574%
*T–15 last sample during previous course (prior to drug holiday), T05 day of restart before first reinfusion, T11 early time-point after re-
exposure (i.e. just before second or third infusion), T 125 later sample (i.e. before third or fourth reinfusion). ADA5 anti-drug antibody;
MS5multiple sclerosis; RA5 rheumatoid arthritis; ELISA5 enzyme-linked immunosorbent assay; OD5 optical density; VSV5 vesicular stoma-
titis virus; ED505 effective median dose; Nab5 neutralizing antibody; s.d.5 standard deviation.
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structures of BPs and the roles of inflammation and under-
lying patient characteristics. A first step that will facilitate
the scientific process of elucidating these mechanisms is the
adoption of clear definitions for terms and concepts related
to immunogenicity, its prediction and associated clinical
events across all communities involved in the immunoge-
nicity area. Thus, ABIRISK is providing their recommenda-
tions as a resource to these communities for their use and
to obtain their feedback on the relevance to long-term
immunogenicity monitoring practices.
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